Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines01:30

Cancer Vaccines

917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence01:22

Development of Immunocompetence

759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations01:51

Vaccinations

51.1K
Overview
51.1K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity01:07

Teratogenicity

3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of endothelial Dlc1 in embryonic vascular development and adult bone marrow hematopoiesis.

Leukemia·2026
Same author

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

European urology open science·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines.

The Lancet. Microbe·2026
Same author

The Biomarkers Consortium: 20 years of advancing precision medicine.

Nature reviews. Drug discovery·2026
Same author

Development of HPV 35 serology assays for assessment of immune responses to HPV 35 after infection and vaccination.

Human vaccines & immunotherapeutics·2026

Related Experiment Video

Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management
01:19

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

252

Prophylactic human papillomavirus vaccines.

Douglas R Lowy1, John T Schiller

  • 1Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. drl@helix.nih.gov

The Journal of Clinical Investigation
|May 4, 2006
PubMed
Summary
This summary is machine-generated.

Prophylactic human papillomavirus (HPV) vaccines show excellent safety and efficacy in preventing cervical cancer and genital warts. Widespread implementation in developing nations remains a key challenge.

More Related Videos

Cancer Vaccines
01:30

Cancer Vaccines

917
Development of Immunocompetence
01:22

Development of Immunocompetence

759

Related Experiment Videos

Last Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management
01:19

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

252
Cancer Vaccines
01:30

Cancer Vaccines

917
Development of Immunocompetence
01:22

Development of Immunocompetence

759

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Human papillomavirus (HPV) is the primary cause of cervical cancer, a leading cancer death cause in women globally.
  • Current research focuses on prophylactic HPV subunit vaccines utilizing virus-like particles (VLPs) derived from the L1 capsid protein.

Purpose of the Study:

  • To review the development and efficacy of prophylactic HPV subunit vaccines.
  • To assess the safety and immunogenicity of HPV vaccines targeting HPV16, HPV18, HPV6, and HPV11.

Main Methods:

  • Review of preclinical research and ongoing development of commercial HPV vaccines by Merck and GlaxoSmithKline.
  • Analysis of vaccine targets, including HPV types responsible for cervical cancer and external genital warts.

Main Results:

  • Vaccines targeting HPV16 and HPV18 are effective against approximately 70% of cervical cancers.
  • The Merck vaccine also targets HPV6 and HPV11, addressing about 90% of external genital warts.
  • Vaccines demonstrate excellent safety, high immunogenicity, and provide complete type-specific protection against persistent infection and lesions.

Conclusions:

  • Prophylactic HPV vaccines offer significant protection against HPV-related diseases.
  • Key challenges include identifying optimal vaccination groups and reducing costs for global accessibility, especially in developing countries where cervical cancer is most prevalent.